3-MMC Stats - Substance Search

Interaction Warnings

⚠ mdma

The neurotoxic effects of MDMA may be increased when combined with other stimulants.

⚠ cocaine

This combination may increase strain on the heart.

Receptor Profile

Receptor Actions

Inhibitors

Serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI)

Other

Serotonin-norepinephrine-dopamine releasing agent (SNDRA)

History & Culture

2012–present

3-MMC was first encountered in Sweden in 2012, emerging on the online research chemical market shortly after the banning of mephedrone in numerous countries. It was created as a designer drug specifically chosen to mimic and replace the functional and structural features of its recently-controlled predecessor. The compound was sold as a research chemical, typically in powdered form, and quickly became a prominent example of contemporary designer drug development in response to prohibition. There is no known or reported medical use of 3-MMC; since its emergence it has been used primarily for recreational purposes.

2016–2023

In 2016, the United Nations Office on Drugs and Crime conducted a critical review of 3-MMC but ultimately decided not to recommend international control. However, following a subsequent period of increased abuse beginning around 2019, this decision was revisited. The earlier assessment was overturned and 3-MMC was placed into Schedule II of the United Nations Convention on Psychotropic Substances 1971 in March 2023, prompting many member nations to implement or strengthen domestic controls.

2023–present

Despite its prohibition as a recreational substance, 3-MMC has attracted interest as a potential pharmaceutical compound. The biotechnology company Clearmind Medicine has been developing 3-MMC for the potential treatment of dyskinesias, with the compound in preclinical research as of August 2023. American biotech company MindMed has filed patents to use 3-MMC for conditions including social anxiety disorder, post-traumatic stress disorder, and as an adjunct in couples therapy. Additionally, the Dutch company Period Pill has been conducting clinical trials investigating 3-MMC for the treatment of menstrual symptoms, with a successful trial completed at the University of Maastricht. The company has sought patent coverage in multiple jurisdictions. The first in-human clinical safety study of 3-MMC was published in December 2024, marking a significant milestone in the compound's transition from unregulated research chemical to potential therapeutic agent.

Subjective Effects

Physical

Spontaneous tactile sensations
Pupil dilation
Perception of decreased weight
Increased perspiration
Teeth grinding: This component can be considered to be less intense when compared with that of MDMA.

Cognitive

Euphoria
Empathy, love and sociability enhancement
Motivation enhancement
Anxiety suppression

Sensory

Auditory

Auditory enhancement

Forked from Subjective Effect Documentation work by Josie Kins, August 2016. Via dose.wiki (CC0).

Toxicity

PsychonautWiki

As with most research chemicals, the long-term effects of 3-MMC have not been researched extensively enough to provide accurate information of its risks and harm. It is strongly recommended that one use harm reduction practices when using this substance.

Addiction & dependence

As with other stimulants, the chronic use of 3-MMC can be considered extremely addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage. It is said that this compound is considerably more addictive than that of mephedrone.

Effect Profile

Curated + 16 Reports

Empathogen 9.6

Strong empathy, euphoria, and sensory enhancement with moderate stimulation

Empathy / Social Openness×3

107.5

Euphoria / Mood Elevation×2

1010

Stimulation×1

79.6

Sensory Enhancement×1

104.4

Catalog BlueLight

Stimulant 5.1

Strong euphoria with strong anxiety/jitters, mild stimulation, low focus

Stimulation / Energy×3

5

Euphoria / Mood Lift×2

10

Focus / Productivity×2

3

Anxiety / Jitters×1

10

Based on reports from:

Erowid Experience Reports PsychonautWiki 3-MMC The Drug Users Bible 3-MMC

Tolerance & Pharmacokinetics

drugs.wiki

Tolerance Decay

Full tolerance 1h Half tolerance 7d Baseline ~14d

Experience Report Analysis

Erowid BlueLight

17 Reports

7 Single-substance

2012–2023 Date Range

15 With Age Data

5 Effects Detected

Demographics

Gender Distribution

Too few reports for a chart: gender is known from 17 reports, and a split is drawn only from 20 reports or more. Counts are shown instead. Why 20?

Male 15 of 17
Female 1 of 17
Not Specified 1 of 17

Age Distribution

Reports Over Time

Effect Analysis

Erowid + Bluelight

Effects aggregated from 16 experience reports (7 single-substance Erowid + 9 Bluelight)

16 Reports

43 Effects Detected

14 Positive

20 Adverse

9 Neutral

Effect Sentiment Distribution

Confidence Distribution

Each bar is the share of reports mentioning the effect; its whisker, and the band on the rows below, is the 95% interval: where the share could plausibly be with other reports of the same kind.

Too few reports for bars: these effects come from 7 single-substance Erowid and 9 analyzed Bluelight reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

Positive Effects 14

Euphoria 11 of 16 84%

Stimulation 9 of 16 85%

Sociability Enhancement 4 of 9 81%

Body High 4 of 9 85%

Empathy 6 of 16 83%

Contentment 3 of 9 92%

Thought Acceleration 3 of 9 75%

Tingling 2 of 9 88%

Focus Enhancement 2 of 9 78%

Music Enhancement 2 of 9 85%

Joy 2 of 9 85%

Libido Enhancement 2 of 9 85%

Orgasm Enhancement 1 of 9 80%

Enhanced Colors 1 of 9 75%

Adverse Effects 20

Muscle Tension 3 of 7 70%

Insomnia 3 of 9 85%

Jaw Clenching 5 of 16 78%

Sedation 2 of 9 80%

Irritability 2 of 9 82%

Emotional Blunting 1 of 9 65%

Nausea 1 of 9 70%

Dry Mouth 1 of 9 75%

Metallic Taste 1 of 9 80%

Headache 1 of 9 70%

Diarrhea 1 of 9 75%

Body Load 1 of 9 80%

Anxiety 1 of 9 85%

Distractibility 1 of 9 80%

Muscle Spasm 1 of 9 90%

Dizziness 1 of 9 85%

Hot Flashes 1 of 9 90%

Cold Flashes 1 of 9 85%

Restlessness 1 of 9 85%

Sadness 1 of 9 80%

Show 9 neutral or unclassified mentions

Sweating 3 of 9

Body Temperature Change 3 of 9

Drowsiness 2 of 9

Visual Vibration 2 of 9

Appetite Suppression 2 of 9

Lightheadedness 1 of 9

Pupil Dilation 1 of 9

Visual Distortions 1 of 9

Appetite Increase 1 of 9

Also reported in combinations. In the 10 3-MMC reports where another drug was taken too, 0 mention hospital, emergency services or an overdose, 0 a seizure and 1 psychosis (too few reports for percentages). In the 7 single-substance reports: 1, 1 and 0. These are not in the figures above: they cannot be put down to 3-MMC alone, and a mention is not always something that happened to the writer.

Real-World Dose Distribution

Erowid

From 16 of 28 recorded dose entries: those that state a weight (mg, g or µg), in routes with at least five of them. Values above Q3 + 3×IQR, far above what people typically take, are left out; they can include real heavy doses and overdoses, not only mistakes.

Oral (n=15)

Median: 100.0mg 25th: 72.5mg 75th: 155.0mg 90th: 176.0mg

Form / Preparation

Most common forms and preparations, as a share of the 11 reports that give one

Too few reports for bars: these forms come from 11 reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

Powder / Crystals 10 of 11

Redose Patterns

Redosing behavior across 13 reports

7 of 13 Redosed

1.9 Avg Doses

60m Median Interval

Too few reports for a chart: redosing is known from 13 reports, and a split is drawn only from 20 reports or more. Counts are shown instead. Why 20?

Single dose 6 of 13
Redosed 7 of 13

Legal Status

UN Convention on Psychotropic Substances 1971 (Schedule II, placed March 2023)

Country	Status	Notes
Austria	Illegal (NPSG)	Prohibited under the Neue-Psychoaktive-Substanzen-Gesetz (New Psychoactive Substances Act). Possession, production, and sale are illegal.
Brazil	Illegal	Listed on Portaria SVS/MS nº 344. Possession, production, and sale are prohibited under this regulation.
China	Controlled	Banned since October 2015 along with numerous other synthetic compounds. This ban significantly impacted global availability as Chinese chemical companies were primary manufacturers.
Czech Republic	Illegal	Banned substance under national drug control legislation.
Germany	Anlage I BtMG	Controlled under Anlage I of the Betäubungsmittelgesetz (Narcotics Act, Schedule I) since December 13, 2014. Manufacturing, possession, import, export, purchase, sale, procurement, and dispensing without license are prohibited.
India	Narcotic	Designated as a narcotic substance on February 8, 2024, making possession, production, and distribution illegal.
Netherlands	List I (Opiumwet)	Initially classified as a List II (soft drug) substance effective October 28, 2021. Subsequently reclassified to List I (hard drug) in April 2024, carrying more severe penalties for possession and distribution.
Poland	II-P Category Drug	Classified as a II-P category controlled substance since April 25, 2024, making possession, production, and distribution illegal.
Sweden	Narcotic	Classified as a narcotic substance under Swedish drug control legislation.
Switzerland	Controlled (Verzeichnis E)	Regulated as a defined derivative of cathinone under Verzeichnis E point 1. Use is permitted for legitimate scientific or industrial purposes only.
Turkey	Illegal	Classified as a controlled drug. Possession, production, supply, and importation are prohibited.
United Kingdom	Class B	Controlled as a Class B substance under the Misuse of Drugs Act 1971 through the cathinone catch-all clause, which covers structurally related compounds.
United States	Schedule I	Illegal as a positional isomer of the controlled substance mephedrone. Explicitly designated as a controlled substance on December 13, 2023, and categorized by the DEA as a Schedule I positional isomer.

3-MMC Stats & Data